Circulating MiRNAs Serum Expression Levels And Clinical Significance Of Prostate Cancer Patients

In the serum of patients with prostate cancer(PCA) as the research object, usi ng quantitative RT-PCR(qRT-PCR) analysis of 3 tumor related miRNAs molecular methods(miRNA-141, mi RNA-152, mi RNA-221) expression level, at the same tim e, expression and analysis of influencing factors of prostate cancer pre abnormaliti es after each miRNAs including gender, age, pathological type, differentiation degr-ee) the correlation between, in order to prostate cancer early diagnosis, effective individualized treatment plan and follow-up after the operation is simple and feasi ble to provide theoretical foundation.To analyze the circulating mi RNA-141 in serum as non-invasive biomarker in patients with prostate cancer, benign prostate hyperplasia(BPH) and healthy individuals(HI), a total of 75 patients with prostate cancer, 52 benign prostate hyperplasia and 40 healthy individuals as controls are enrolled into this study. Total RNA was isolated from serum samples and the circulating levels of circulating miRNA-141 were determined using a quantitative real-time polymerase chain reaction. The serum levels of mi RNA-141 were significantly higher in patients with PCa compared to patients with BPH and healthy controls(P<0.0001, and P<0.0001 respectively). The expression levels of miRNA-141 could differentiate PCa from BPH and healthy controls with high diagnosis performance, with an AUC of 0.785 and 0.801, respectively. There was no statistically significant difference in the serum miRNA-141 levels between patients with BPH and healthy individuals(P>0.05). Serum miRNA-141 levels were also found to be related to the Gleason scores and metastatic status of patients with PCa(P<0.05), respectively, and patients with higher Gleason scores had higher serum miRNA-141 levels. No relationships were detected between mi RNA-141 level and the patient’s age, biochemistry failure status and serum PSA level(P>0.05 for all comparisons). Circulating miRNA-141 could serve as non-invasive biomarker for prostate cancer diagnosis, staging and prognosis prediction.To analysis circulating miRNA-152 and mi RNA-221 serum expression levels and clinical significance of prostate cancer patients, 48 prostate cancer patients, 32 patients with benign prostatic hyperplasia and 24 healthy volunteers over the same period as a control group,analyze the expression levels of serum miRNA-152, miRNA-221 and the correlation between PSA and Gleason’s. Results show that the expression of miRNA-152 in prostate cancer patients is significantly lower than the normal population and the patients with benign prostatic hyperplasia(P<0.05), no statistically significant difference between benign prostatic hyperplasia and normal control group(P>0.05); miRNA-221 expression levels in prostate cancer patients was significantly lower than the normal population and in patients with benign prostatic hyperplasia, the expression level in benign prostatic hyperplasia also lower than the normal population, the differences were statistically significant(P<0.05); the expression level of miRNA-152 in prostate cancer patients were significant negative correlation with Gleason score(P <0.05), but serum PSA levels were not correlation(P>0.05), the expression level of miRNA-221 in prostate cancer patients were significant negative correlation with serum PSA and Gleason score. mi RNA-152 and miRNA-221 may be involved in prostate through complex regulatory process, invasion and provides an experimental basis for early diagnosis of prostate cancer and determine the course.